JCR Pharmaceuticals Co Ltd 2025 IR
The report outlines JCR Pharmaceuticals' performance and sustainability initiatives for FY2024, marking the company's upcoming 50th anniversary. Despite facing a challenging financial year with an operating loss due to licensing delays and inventory write-offs, JCR continued its heavy investment in R&D, particularly in its proprietary J-Brain Cargo (JBC) blood-brain barrier penetration technology. Key achievements include completing patient enrollment for the global Phase III trial of JR-141 and advancing clinical trials for other rare disease therapies. The company also progressed construction on its new formulation plant in Kobe and continued to implement its human capital and climate strategies in alignment with TCFD recommendations.
Company: JCR Pharmaceuticals Co Ltd
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 38
JCR Pharmaceuticals Co Ltd
Integrated Report
The report outlines JCR Pharmaceuticals' performance and sustainability initiatives for FY2024, marking the company's upcoming 50th anniversary. Despite facing a challenging financial year with an operating loss due to licensing delays and inventory write-offs, JCR continued its heavy investment in R&D, particularly in its proprietary J-Brain Cargo (JBC) blood-brain barrier penetration technology. Key achievements include completing patient enrollment for the global Phase III trial of JR-141 and advancing clinical trials for other rare disease therapies. The company also progressed construction on its new formulation plant in Kobe and continued to implement its human capital and climate strategies in alignment with TCFD recommendations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women in Management
Employees